BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 214090)

  • 1. Inhibition cyclic nucleotide phosphodiesterase by FPL 55712, an SRS-A antagonist.
    Chasin M; Scott C
    Biochem Pharmacol; 1978; 27(16):2065-7. PubMed ID: 214090
    [No Abstract]   [Full Text] [Related]  

  • 2. Different sensitivites of cyclic nucleotide phosphodiesterases of rat brain and lung to inhibition by new anti-allergic chromones [proceedings].
    Saeed SA; Butt NM; Spicer JW; Warren BT
    Biochem Soc Trans; 1979 Dec; 7(6):1308-10. PubMed ID: 231533
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of lung cyclic AMP- and cyclic GMP-phosphodiesterases by flavonoids and other chromone-like compounds.
    Ruckstuhl M; Landry Y
    Biochem Pharmacol; 1981 Apr; 30(7):697-702. PubMed ID: 6264919
    [No Abstract]   [Full Text] [Related]  

  • 4. Selective inhibition of rat lung cyclic AMP phosphodiesterase and cyclic GMP phosphodiesterase by cyclic nucleotides and their analogues and various drugs [proceedings].
    Butt NM; Saeed SA; Collier HO
    Biochem Soc Trans; 1980 Jun; 8(3):380-1. PubMed ID: 6249674
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibition of human lung cyclic GMP and cyclic AMP phosphodiesterases by certain nucleosides, nucleotides, and pharmacological phosphodiesterase inhibitors.
    Glass WF; Moore JB
    Biochem Pharmacol; 1979 Apr; 28(7):1107-12. PubMed ID: 87197
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition of human lymphocyte cyclic nucleotide phosphodiesterases by the chlorinated adenosine analog DTA-35.
    Hurwitz MY; Hurwitz RL; Edstrom RD
    J Enzyme Inhib; 1987; 1(4):267-74. PubMed ID: 2854846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacologic value of cyclic nucleotide phosphodiesterase inhibitors].
    Nemoz G; Prigent AF
    Ann Pharm Fr; 1984; 42(2):99-112. PubMed ID: 6091520
    [No Abstract]   [Full Text] [Related]  

  • 8. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
    Kass DA
    Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
    [No Abstract]   [Full Text] [Related]  

  • 9. Methylxanthine inhibitors of phosphodiesterases.
    Wells JN; Miller JR
    Methods Enzymol; 1988; 159():489-96. PubMed ID: 2457788
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes--their potential utility in the therapy of asthma.
    Nicholson CD; Shahid M
    Pulm Pharmacol; 1994 Feb; 7(1):1-17. PubMed ID: 8003849
    [No Abstract]   [Full Text] [Related]  

  • 11. Studies on the inhibition of phosphodiesterase-catalyzed cyclic AMP and cyclic GMP breakdown and relaxation of canine tracheal smooth muscle.
    Polson JB; Krzanowski JJ; Fitzpatrick DF; Szentivanyi A
    Biochem Pharmacol; 1978 Jan; 27(2):254-6. PubMed ID: 203292
    [No Abstract]   [Full Text] [Related]  

  • 12. Differential effects of cyclic nucleotides and their analogs and various agents on cyclic GMP-specific and cyclic AMP-specific phosphodiesterases purified from guinea pig lung.
    Davis CW; Kuo JF
    Biochem Pharmacol; 1978 Jan; 27(1):89-95. PubMed ID: 202285
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacological inhibition of calmodulin-sensitive phosphodiesterases.
    Ilien B; Ruckstuhl M; Landry Y
    J Pharmacol; 1982; 13(2):307-16. PubMed ID: 6285085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic nucleotide phosphodiesterase in heart and aorta of spontaneously hypertensive rats.
    Sharma RV; Bhalla RC
    Biochim Biophys Acta; 1978 Oct; 526(2):479-88. PubMed ID: 214127
    [No Abstract]   [Full Text] [Related]  

  • 15. Selective inhibition of separated forms of cyclic nucleotide phosphodiesterase from rat heart by some cardio- or vaso-active butenolide derivatives.
    Némoz G; Prigent AF; Picq M; Pacheco H
    Biochem Pharmacol; 1982 Nov; 31(21):3353-8. PubMed ID: 6293510
    [No Abstract]   [Full Text] [Related]  

  • 16. Dihydro- and tetrahydroisoquinolines as inhibitors of cyclic nucleotide phosphodiesterases from dog heart. Structure-activity relationships.
    Van Inwegen RG; Salaman P; St Georgiev V; Weinryb I
    Biochem Pharmacol; 1979 Apr; 28(8):1307-12. PubMed ID: 87199
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of polyphloretin phosphate (PPP) and quinterenol of cyclic nucleotide phosphodiesterase activities.
    Curtis-Prior PB; Chan YH
    Pharmacol Res Commun; 1981 Apr; 13(4):331-7. PubMed ID: 6270700
    [No Abstract]   [Full Text] [Related]  

  • 18. Cyclic nucleotide phosphodiesterase activities of the embryonic chick ovary.
    Teng CT; Buchler B; Teng CS
    Gen Comp Endocrinol; 1981 Aug; 44(4):409-17. PubMed ID: 6167486
    [No Abstract]   [Full Text] [Related]  

  • 19. Selective phosphodiesterase inhibition and alterations of cardiac function by alkylated xanthines.
    Mushlin P; Boerth RC; Wells JN
    Mol Pharmacol; 1981 Jul; 20(1):179-89. PubMed ID: 6270531
    [No Abstract]   [Full Text] [Related]  

  • 20. Flavonoids are selective cyclic GMP phosphodiesterase inhibitors.
    Ruckstuhl M; Beretz A; Anton R; Landry Y
    Biochem Pharmacol; 1979; 28(4):535-8. PubMed ID: 218594
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.